MCID: PDT040
MIFTS: 31

Pediatric Hypertension

Categories: Rare diseases

Aliases & Classifications for Pediatric Hypertension

MalaCards integrated aliases for Pediatric Hypertension:

Name: Pediatric Hypertension 50

Classifications:



Summaries for Pediatric Hypertension

MalaCards based summary : Pediatric Hypertension is related to cataract, autosomal dominant congenital 4 and potato nose. An important gene associated with Pediatric Hypertension is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Peptide hormone metabolism and Renin secretion. The drugs Ramipril and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and brain.

Related Diseases for Pediatric Hypertension

Graphical network of the top 20 diseases related to Pediatric Hypertension:



Diseases related to Pediatric Hypertension

Symptoms & Phenotypes for Pediatric Hypertension

Drugs & Therapeutics for Pediatric Hypertension

Drugs for Pediatric Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
2
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
5
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 11103-57-4, 68-26-8 445354
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
11 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
14 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
15 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3
16 Immunosuppressive Agents Phase 4,Phase 2,Phase 3
17 Liver Extracts Phase 4,Phase 2,Phase 3
18 Bone Density Conservation Agents Phase 4
19 Micronutrients Phase 4
20 Retinol palmitate Phase 4,Phase 2
21 Trace Elements Phase 4
22 Vitamins Phase 4,Phase 2
23 Ergocalciferols Phase 4
24 retinol Nutraceutical Phase 4,Phase 2
25 Calciferol Nutraceutical Phase 4
26 Vitamin D2 Nutraceutical Phase 4
27
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
28
Valsartan Approved, Investigational Phase 3,Phase 1 137862-53-4 60846
29
Candesartan Approved Phase 3 139481-59-7 2541
30
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
31
Enalapril Approved, Vet_approved Phase 3,Phase 2 75847-73-3 5362032 40466924
32
Enalaprilat Approved Phase 3,Phase 2 76420-72-9 6917719
33
Isradipine Approved Phase 2, Phase 3 75695-93-1 3784
34
Propranolol Approved, Investigational Phase 2, Phase 3,Phase 1 525-66-6 4946
35
Brinzolamide Approved Phase 3 138890-62-7 68844
36
Betaxolol Approved Phase 3 659-18-7, 63659-18-7 2369
37
Timolol Approved Phase 3 26839-75-8 33624 5478
38
Losartan Approved Phase 3,Phase 2 114798-26-4 3961
39
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
40
Iloprost Approved, Investigational Phase 2, Phase 3, Phase 1 78919-13-8 6443959
41
Eplerenone Approved Phase 3 107724-20-9 150310 443872
42
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
43
Amlodipine Approved Phase 3 88150-42-9 2162
44
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
45
Travoprost Approved Phase 3,Phase 1 157283-68-6 5282226
46
Hydrochlorothiazide Approved, Vet_approved Phase 3 58-93-5 3639
47
Telmisartan Approved, Investigational Phase 3,Phase 2 144701-48-4 65999
48
Latanoprost Approved, Investigational Phase 3,Phase 1 130209-82-4 5282380 5311221
49
Macitentan Approved Phase 3 441798-33-0
50
Treprostinil Approved, Investigational Phase 3,Phase 2 81846-19-7 54786 6918140

Interventional clinical trials:

(show top 50) (show all 147)

id Name Status NCT ID Phase Drugs
1 Treatment of Pediatric Hypertension With Altace Trial Completed NCT00044265 Phase 4 ramipril
2 Comparison of Immunosuppression Protocols After LTx in Children Completed NCT00195988 Phase 4 tacrolimus, steroids, mycophenolate mofetil
3 Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Completed NCT01895894 Phase 4 Mycophenolate mofetil
4 Efficacy of Vitamin D Supplementation in Obese Children Enrolling by invitation NCT02956408 Phase 4
5 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3
6 A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension Completed NCT00171028 Phase 3 valsartan
7 A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension Completed NCT02451150 Phase 3 Azilsartan
8 Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age Completed NCT00244634 Phase 3 candsartan cilexetil
9 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD Completed NCT01617681 Phase 3 VAL489;VAL489 matching placebo
10 Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects Completed NCT00255528 Phase 3 metoprolol succinate
11 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed NCT00255502 Phase 3 metoprolol succinate
12 Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age Completed NCT00244621 Phase 3 candesartan cilexetil (Atacand);candesartan cilexetil (Atacand);candesartan cilexetil (Atacand)
13 Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age Completed NCT00244595 Phase 3 candsartan cilexetil
14 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01150357 Phase 3 Aliskiren (6.25/12.5/25 mg);Aliskiren (37.5/75/150 mg);Aliskiren (150/300/600 mg)
15 A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age Completed NCT00171041 Phase 3 valsartan
16 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01151410 Phase 3 Aliskiren;Enalapril
17 Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients Completed NCT01007994 Phase 2, Phase 3 New Medication: Enalapril, Isradipine, Propranolol
18 Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension Completed NCT00061516 Phase 3 BETAXON (levobetaxolol HCl);AZOPT (brinzolamide)
19 Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension Completed NCT00061542 Phase 3 BETOPTIC S (betaxolol HCl);Timolol Gel-forming Solution (TGFS)
20 Bosentan in Children With Pulmonary Arterial Hypertension Completed NCT00319267 Phase 3 Bosentan
21 Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension Completed NCT01223352 Phase 3 bosentan
22 Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337) Completed NCT00756938 Phase 3 losartan potassium
23 FUTURE 3 Study Extension Completed NCT01338415 Phase 3 Bosentan;Bosentan
24 Bosentan in Children With Pulmonary Arterial Hypertension Extension Study Completed NCT00319020 Phase 3 Bosentan
25 Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) Completed NCT00690612 Phase 3 candesartan cilexetil
26 Sedation With Dexmedetomidine During Cardiac Catheterization Completed NCT01072643 Phase 2, Phase 3 Dexmedetomidine
27 Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery Completed NCT01310751 Phase 2, Phase 3 iloprost nebuliser solusion;distilled water
28 The Long-Term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years Completed NCT00147615 Phase 3 Eplerenone
29 Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD) Completed NCT01598441 Phase 3 iloprost nebuliser solution;distilled water
30 A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children. Completed NCT00147589 Phase 3 Eplerenone
31 An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) Completed NCT00568178 Phase 3 Losartan Potassium;Comparator: amlodipine besylate;Enalapril Maleate
32 Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Completed NCT01652664 Phase 3 Travoprost 0.004% PQ ophthalmic solution;Timolol, 0.5% or 0.25% ophthalmic solution;Travoprost Vehicle
33 Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age Completed NCT01365481 Phase 3 Valsartan;amlodipine;Hydrochlorothiazide
34 Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients Completed NCT00221845 Phase 3 ACE Inhibition;Intensified Blood Pressure Control;Add-on Angiotensin Receptor Blockade
35 Trabeculectomy With MMC Versus Ahmed Glaucoma Implant for Treatment of Pediatric Aphakic Glaucoma Completed NCT00371072 Phase 2, Phase 3
36 A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children Completed NCT00159874 Phase 3 Sildenafil citrate;Sildenafil citrate;Sildenafil citrate
37 A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma. Completed NCT00716859 Phase 3 Timolol;latanoprost
38 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed NCT00741156 Phase 3 Enalaprilat
39 Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension Completed NCT00660179 Phase 3 macitentan (ACT-064992);macitentan (ACT-064992);placebo
40 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension Recruiting NCT02791438 Phase 3 TAK-536 2.5 mg;TAK-536 5 mg
41 An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension Recruiting NCT02235909 Phase 3 Azilsartan Medoxomil;Losartan;Placebo for Azilsartan Medoxomil;Placebo for Losartan
42 A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) Recruiting NCT01824290 Phase 3 Tadalafil;Placebo
43 Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Recruiting NCT02562235 Phase 3 Riociguat (Adempas, BAY63-2521)
44 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension Active, not recruiting NCT01642407 Phase 3 Sildenafil
45 Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension Active, not recruiting NCT00667823 Phase 3 Macitentan
46 Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery Not yet recruiting NCT02865733 Phase 3 Remodulin;distilled water
47 The Assessment of Right Ventricular Contractility in Response to Sildenafil Suspended NCT00742014 Phase 3 Sildenafil
48 A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) Terminated NCT00447603 Phase 3 hydrochlorothiazide (+) losartan potassium;losartan potassium;Placebo for Losartan;Placebo for Losartan/HCTZ
49 A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents Terminated NCT00389519 Phase 3 ramipril;placebo
50 Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity Terminated NCT01709136 Phase 2, Phase 3 Sirolimus

Search NIH Clinical Center for Pediatric Hypertension

Genetic Tests for Pediatric Hypertension

Anatomical Context for Pediatric Hypertension

MalaCards organs/tissues related to Pediatric Hypertension:

39
Liver, Kidney, Brain, Heart, Bone, Lung, Testes

Publications for Pediatric Hypertension

Articles related to Pediatric Hypertension:

(show top 50) (show all 119)
id Title Authors Year
1
Can Pediatric Hypertension Criteria Be Simplified? A Prediction Analysis of Subclinical Cardiovascular Outcomes From the Bogalusa Heart Study. ( 28223474 )
2017
2
Pediatric Hypertension: Provider Perspectives. ( 28620629 )
2017
3
Definition of pediatric hypertension: are blood pressure measurements on three separate occasions necessary? ( 28077857 )
2017
4
Hypertension Canada's 2017 Guidelines for the Diagnosis,A Assessment, Prevention, and Treatment ofA Pediatric Hypertension. ( 28449829 )
2017
5
Primary Pediatric Hypertension: Current Understanding and Emerging Concepts. ( 28780627 )
2017
6
Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 28553631 )
2017
7
In-Clinic Blood Pressure Prediction of Normal Ambulatory Blood Pressure Monitoring in Pediatric Hypertension Referrals. ( 27205889 )
2016
8
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, and Assessment of Risk of Pediatric Hypertension. ( 27118292 )
2016
9
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27643136 )
2016
10
Vascular Aging: Lessons From Pediatric Hypertension. ( 27040097 )
2016
11
Assessment of Left Ventricular Mass and Hypertrophy by Cardiovascular Magnetic Resonance Imaging in Pediatric Hypertension. ( 26988578 )
2016
12
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27754179 )
2016
13
Pediatric Hypertension: Are Pediatricians Following Guidelines? ( 27659546 )
2016
14
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27643063 )
2016
15
Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. ( 27940711 )
2016
16
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27754136 )
2016
17
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27754169 )
2016
18
Pharmacologic Management of Pediatric Hypertension. ( 26597490 )
2016
19
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27643124 )
2016
20
Pharmacologic Treatment of Pediatric Hypertension. ( 27048353 )
2016
21
Re: Pediatric Hypertension and Cardiac Hypertrophy. ( 26739585 )
2016
22
Pediatric hypertension: a growing problem. ( 25634711 )
2015
23
Pediatric hypertension in the Eastern Province of Saudi Arabia. ( 25987114 )
2015
24
Racial Differences of Pediatric Hypertension in Relation to Birth Weight and Body Size in the United States. ( 26176843 )
2015
25
Cardiovascular target organ damage could have been detected in sustained pediatric hypertension. ( 26024395 )
2015
26
Is Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension? ( 26140344 )
2015
27
Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity. ( 26389821 )
2015
28
Pediatric hypertension: a pharmacological review. ( 25898873 )
2015
29
Hypertension editors' picks: pediatric hypertension. ( 25855321 )
2015
30
Pediatric hypertension: a pharmacological review. ( 25898872 )
2015
31
The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension. ( 25794952 )
2015
32
Abnormalities of vascular structure and function in pediatric hypertension. ( 26275663 )
2015
33
Recent clinical and translational advances in pediatric hypertension. ( 25712720 )
2015
34
Diagnosis of primary versus secondary pediatric hypertension. ( 25594296 )
2015
35
Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. ( 27129124 )
2014
36
Pediatric Hypertension Specialists' Perspectives About Adolescent Hypertension Management: Implications for Primary Care Providers. ( 25398627 )
2014
37
Pediatric hypertension: An update on a burning problem. ( 24944755 )
2014
38
Autonomic nervous system dysregulation in pediatric hypertension. ( 24633841 )
2014
39
Gene polymorphisms of adducin GLY460TRP, ACE I/D, AND AGT M235T in pediatric hypertension patients. ( 25262176 )
2014
40
U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms? ( 24720583 )
2014
41
Essential pediatric hypertension: defining the educational needs of primary care pediatricians. ( 25063988 )
2014
42
Pediatric hypertension: often missed and mismanaged. ( 24701598 )
2014
43
Clinical predictors and impact of ambulatory blood pressure monitoring in pediatric hypertension referrals. ( 25065681 )
2014
44
Response to "U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms?". ( 24720549 )
2014
45
Concordance of Measures of Left-Ventricular Hypertrophy in Pediatric Hypertension. ( 24253610 )
2013
46
Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. ( 24337365 )
2013
47
Executive Function and Cerebrovascular Reactivity in Pediatric Hypertension. ( 23877480 )
2013
48
Serum urate: a biomarker or treatment target in pediatric hypertension? ( 23736817 )
2013
49
The changing face of pediatric hypertension in the era of the childhood obesity epidemic. ( 23138756 )
2013
50
Pediatric Hypertension: The Year in Review. ( 23960265 )
2013

Variations for Pediatric Hypertension

Expression for Pediatric Hypertension

Search GEO for disease gene expression data for Pediatric Hypertension.

Pathways for Pediatric Hypertension

Pathways related to Pediatric Hypertension according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.22 ACE AGT
2 10.44 ACE AGT

GO Terms for Pediatric Hypertension

Biological processes related to Pediatric Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.46 ACE AGT
2 regulation of blood pressure GO:0008217 9.43 ACE AGT
3 positive regulation of protein tyrosine kinase activity GO:0061098 9.37 ACE AGT
4 blood vessel remodeling GO:0001974 9.32 ACE AGT
5 regulation of vasoconstriction GO:0019229 9.26 ACE AGT
6 angiotensin maturation GO:0002003 9.16 ACE AGT
7 positive regulation of protein binding GO:0032092 9.1 ADD1
8 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE AGT
9 regulation of renal output by angiotensin GO:0002019 8.62 ACE AGT

Sources for Pediatric Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....